Convalescent plasma therapy for COVID-19 patients : a protocol of a prospective meta-analysis of randomized controlled trials by Szakó, Lajos et al.
METHODOLOGY Open Access
Convalescent plasma therapy for COVID-19
patients: a protocol of a prospective meta-
analysis of randomized controlled trials
Lajos Szakó1,2, Nelli Farkas1,3, Szabolcs Kiss1,4, Szilárd Váncsa1,2, Noémi Zádori1,2, Nóra Vörhendi1,2, Bálint Erőss1,
Péter Hegyi1,5 and Hussain Alizadeh4,6*
Abstract
Background: Coronavirus disease 2019 (COVID-19) is an infection with possible serious consequences. The plasma
of recovered patients might serve as treatment, which we aim to assess in the form of a prospective meta-analysis
focusing on mortality, multi-organ failure, duration of intensive care unit stay, and adverse events.
Methods: A systematic search was conducted to find relevant registered randomized controlled trials in five trial
registries.
A comprehensive search will be done continuously on a monthly basis in MEDLINE (via PubMed), Embase,
Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science to find the results of previously
registered randomized controlled trials. The selection will be done by two independent authors. Data extraction will
be carried out by two other independent reviewers. Disagreements will be resolved by a third investigator.
An update of the search of the registries and the first search of the databases will be done on the 21st of July.
Data synthesis will be performed following the recommendations of the Cochrane Collaboration. In the case of
dichotomous outcomes (mortality and organ failure), we will calculate pooled risk ratios with a 95% confidence
interval (CI) from two-by-two tables (treatment Y/N, outcome Y/N). Data from models with multivariate adjustment
(hazard ratios, odds ratio, risk ratio) will be preferred for the analysis. P less than 0.05 will be considered statistically
significant. In the case of ICU stay, weighted mean difference with a 95% confidence interval will be calculated.
Heterogeneity will be tested with I2, and χ2 tests. Meta-analysis will be performed if at least 3 studies report on the
same outcome and population.
Discussion: Convalescent plasma therapy is a considerable alternative in COVID-19, which we aim to investigate in
a prospective meta-analysis.
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Background
There is currently an outbreak of respiratory disease
caused by a novel coronavirus. The virus has been
named “SARS-CoV-2,” and the disease it causes has
been named “coronavirus disease 2019” (COVID-19).
The outbreak has affected almost every country of the
world, and as of 5 July 2020, a total of 11,046,917 con-
firmed cases and 526,465 deaths had been reported
(www.who.int). Recently, two papers have been pub-
lished reporting on efficient and safe vaccines, [1, 2] and
several others are under investigation and approval in
phase III. Since widespread vaccination takes time, alter-
native treatments are still needed in the early stage of
the disaese. International randomized, controlled trials
investigating the effect of treatments in patients hospital-
ized with COVID-19 have been launched (recovery and
solidarity). The RECOVERY trial so far demonstrated
the efficacy of dexamethasone in patients receiving ei-
ther invasive mechanical ventilation or oxygen alone [3].
Among the treatment strategies under investigation is
the administration of convalescent plasma collected
from individuals who have recovered from COVID-19
[4–7]. Use of convalescent plasma was studied in out-
breaks of other respiratory infections, including the 2003
SARS-CoV-1 epidemic, the 2009–2010 H1N1 influenza
virus pandemic, and the 2012 MERS-CoV epidemic [8–
10]. The effectiveness of convalescent plasma was
highlighted in these studies, and none of the studies
demonstrated adverse events. Therefore, it is essential to
study the safety and efficacy of COVID19 convalescent
plasma in clinical trials. Multiple published and unpub-
lished studies have now reported on the use of convales-
cent plasma to treat severely or critically ill COVID-19
patients, without unexpected or severe adverse events.
In the sole randomized controlled trial reported to date,
critically ill but not intubated patients, receiving conva-
lescent plasma showed more frequent and faster clinical
improvement compared to controls. However, the trial
was terminated early due to a lack of eligible patients at
the study sites in China [11]. The results from this RCT,
and many other systematic works, which were not con-
ducted in a prospective manner support the concept that
convalescent plasma should be used before COVID-19 is
life-threatening to clear the virus more rapidly and avoid
further tissue damage, rather than using this approach
to treat patients with inflammatory end-stage organ fail-
ure [12–14]. Although none of these works aimed to in-
clude only randomized controlled trials in a prospective
manner, but they provide quantitative synthesis of the
available data. Multiple ongoing clinical trials are investi-
gating the use of convalescent plasma in patients with
less severe infection, or prophylactically in highly sus-
ceptible individuals, such as exposed health care workers
or family caregivers of COVID-19 patients, situations
predicted to result in more potential benefit from pas-
sive antibody transfer.
COVID-19 is a newly emerging disease, and there is
not much evidence on its treatment. Thus, applying a
prospective approach of a comprehensive evaluation of
novel therapies is desirable, which can be achieved by
the use of prospective meta-analysis (PMA). As the
question requires sufficient statistical power, PMA also
proves to be beneficial. Furthermore, as the hypotheses,
selection criteria, and intended analyses are stated before
the availability of the results of the actual randomized
trials, it overcomes the limitations of traditional, retro-
spective meta-analyses [15].
We aim to assess the efficacy of convalescent plasma
treatment of COVID-19 patients for the outcomes of
mortality, multi-organ failure, and duration of intensive
care unit (ICU) stay in a prospective meta-analysis.
Methods
The protocol is based on the Preferred Reporting Items
for Systematic review and Meta-Analysis Protocols
(PRISMA-P) statement [16]. Throughout the review
process, the recommendations of the Cochrane Hand-
book for Systematic Reviews of Interventions will be
followed [17].
This protocol has been registered at PROSPERO Inter-
national prospective register of systematic reviews in ad-
vance under the number of CRD42020197442.(https://
www.crd.york.ac.uk/prospero/).
Systematic search and selection of trial registries
A systematic search was carried out on 15 June 2020
with the following search key: COVID 19 OR “SARS-
CoV2” OR “2019-nCoV” in the ClinicalTrials.gov, EU
Clinical Trial Register, International Standard Rando-
mised Controlled Trial Number (ISRCTN) registry,
Australia and New Zealand Clinical Trial Registry
(ANZCTR), and NIPH Clinical Trials Search registry to
find eligible, registered randomized controlled trials.
Two independent review authors performed the selec-
tion first based on the title, then based on the full proto-
col individually. In the case of disagreements, a third
investigator was involved. A trial protocol proved to be
eligible by title if it contained the term “plasma” in the
context of intervention. A protocol was included in the
level of full-text selection if it was a two-arm, random-
ized trial reporting on at least one of the populations
and outcomes in question. All included patients should
be PCR-confirmed COVID-19 cases, which will be di-
vided into four subpopulations: P1: respiratory involve-
ment (hypoxia, pneumonia, acute respiratory distress
syndrome, requirement of oxygenation or ventilation);
P2: patients admitted to the intensive care unit or are
critically ill; P3: hospitalized patients without restriction
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on the severity, including mild, moderate, severe, and
critically ill patients; P4: severe condition, defined as fol-
lowing the most recent World Health Organization
(WHO) classification; intervention (I): convalescent
plasma; control (C): placebo or any other active control;
outcomes (O): mortality at any points of time after base-
line, intensive care unit stay, multi-organ failure, adverse
events. To quantify the level of agreement, Cohen’s
kappa of both stages of the selection was calculated. The
selection process and Cohen’s kappa results are pre-
sented in Fig. 1. Details of the included protocols are
shown in Table 1. Reasons for exclusion on the level of
full-text protocol are presented in Table 2.
Systematic search and selection of databases
A systematic search will be performed on 21 July 2020
in four scientific databases, MEDLINE (via PubMed),
Embase, Cochrane Central Register of Controlled Trials
(CENTRAL), and Web of Science, for randomized con-
trolled trials (RCT). The following query will be used in
all databases without any filters or restrictions: ((COVID
19 OR “SARS-CoV2” OR “2019-nCoV”) AND (plasma
OR serotherapy OR “passive immun*”)). Reference lists
of eligible articles and citing articles (via Google Scholar
search engine) will also be screened to capture all rele-
vant studies.
After the automatic and manual removal of duplicates
using a reference management software (EndNote X9,
Clarivate Analytics), two review authors will independ-
ently screen titles, abstracts, and full-texts against prede-
fined eligibility criteria. A third review author will resolve
any disagreements at each level of the selection process.
Inclusion criteria specified any RCTs that are reporting
on the population and outcomes (mortality, multi-organ
failure, duration of intensive care unit stay, adverse
events) in question, as stated above. We will exclude
non-randomized clinical trials and trials not reporting
on the population and outcomes in question. In the case
of overlapping study populations and updates, we will
include the study with a higher patient number.
Updates on the systematic searches
Regarding the trial registries and scientific databases, we
intend to extract all records every month with the same
Fig. 1 Prisma flowchart of the selection process and the results of Cohen’s kappa
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Plasma therapy details (dose, titer, etc.) Comparison(s) Outcomes
Mortality MOF ICU
stay
Adult COVID-19 patients with respiratory involvement (mechanical ventilation, pneumonia, ARDS, etc.)
NCT04405310
July 2020 80 250mL of CP Placebo + + +
NCT04421404















80 2 units of CP SMT + + −
NCT04374487









June 2020 40 400mL of CP given as 200 mL over 2 h in 2
consecutive days + SMT




126 200mL of CP SMT + − +
NCT04358783




80 2 units of CP SMT + + −
NCT04385199




60 2 × 200mL of CP SMT + + +
NCT04380935
August 2020 60 CP + SMT SMT + + +




231 2 units of CP (between 400 and 500mL) SMT + − −
NCT04342182
July 2020 426 300mL of CP SMT + − −
NCT04347681




500 400mL (2 units) of CP Human Ig + + +
Adult, severe COVID-19 patients
NCT04385043




20 400mL of CP + SMT 200mL of CP + SMT + + +
SMT
NCT04364737
April 2023 300 250-500mL of CP Placebo + − +
NCT04346446
May 2020 29 CP + SMT Placebo + SMT + + +
May 2021 400 2 units of CP for 3 days + SMT SMT + − +
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methodology. The first systematic search and update on
the trial registries will be on 21 July 2020.
Data extraction
A standardized data extraction form will be developed a
priori and will be piloted by the authors performing the
data extraction. Two independent reviewers will extract
data from all included studies. The following data will be
extracted: first author, year of publication, study loca-
tion, study design, study population, the type and details
of interventions received, mean age, sex, number of pa-
tients in each group, inclusion criteria, and outcomes.
Outcomes will include mortality, multi-organ failure,
and intensive care unit stay. Discrepancies will be re-
solved by consensus and the involvement of a third
author. All data will be compiled in an Excel spreadsheet
(Office 365, Microsoft, Redmond, WA, USA) for
analysis.
Statistical analysis
Data synthesis will be performed using the methods rec-
ommended by the working group of the Cochrane
Collaboration [11]. Data from models with multivariate
adjustment (hazard ratios, odds ratio, risk ratio) will be
preferred for the analysis. In the case of dichotomous
outcomes (mortality and organ failure), we will calculate
pooled risk ratios with a 95% confidence interval from
two-by-two tables (treatment Y/N, outcome Y/N), if
multivariate results are not available. P less than 0.05
will be considered statistically significant. Statistical ana-
lysis will be performed using random effects model. In
the case of ICU stay, weighted mean difference with a
95% confidence interval will be calculated. Heterogeneity
will be tested with I2, and χ2 tests, p less than 0.1, will
indicate significant heterogeneity.
Meta-analysis will be performed using STATA v.16
(StataCorp. 2019, College Station, TX: StataCorp LLC.),
Comprehensive Meta-Analysis v.3 (Biostat 2013, Engle-
wood NJ), and R v.4.0.0 (R Core Team 2020, Vienna,
Austria) software if at least three studies of same out-
comes, assessed at the same point of time after the base-
line are available.
A Trial Sequential Analysis (TSA 0.9.5.10.) will also be
performed to quantify the statistical reliability and to












April 2021 105 200–250mL of CP Standard plasma + − −




236 400mL of CP + SMT SMT + + +
NCT04345991












1200 500mL of CP SMT + − +
NCT04345523




60 2 units of CP in 24 h 2 units of standard





333 10–15mL/kg of CP (5–10 mL/h infusion rate) Placebo + SMT + + +
NCT04377568
May 2022 100 10mL/kg (max 500 mL) of CP + SMT SMT + + +
NCT04395170
June 2021 75 2 units of CP in 3 days Anti-COVID-19 human Ig + − +
SMT
NCT04344535
August 2021 500 450–550mL of CP 450–550mL of standard
plasma
+ − −
MOF multiorgan failure, ICU intensive care unit, COVID-19 coronavirus disease 2019, ARDS acute respiratory distress syndrome, CP convalescent plasma, SMT
standard medical therapy, Ig immunoglobulin
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estimate the optimal information size (OIS), if it is pos-
sible. We plan to perform the TSA for every included
outcome. In the case of the Z curve, a p value less than
0.05 will be considered significant.
The presence of publication bias will be assessed visu-
ally by examining a funnel plot, as well as statistically by
using Egger’s regression method if at least 8 studies are
available. We will also use the trim and fill method to
address this question [18].
If possible, subgroups of treatment modalities (dose
and administration of plasma), age (< 18 years, 18–65
year, > 65 years), gender, and comorbidities will be pre-
sented. In the case of missing data, the corresponding
authors will be contacted, or if individual patient data is
available the missing variables will be calculated.
Risk of bias and certainty of the evidence
The quality of all the included studies will be independ-
ently assessed by two reviewers using the Revised
Cochrane risk-of-bias tool for randomized trials (RoB 2)
[19]. Bias will be evaluated in five distinct domains:
randomization process, deviations from intended inter-
ventions, missing outcome data, measurement of the out-
come, and selection of the reported results. Within each
domain, one or more signaling questions will be answered,
which will lead to the judgments of the level of risk of bias:
low (low for all domains), some concerns (some concerns
in at least two domains), and high (at least one domain or
some concerns for multiple domains) risk of bias. The re-
sults of the risk of bias assessment will be summarized
narratively with full assessments, furthermore, a figure de-
scribing the results will be also published. We plan to per-
form the risk of bias assessment for every included
Table 2 Excluded protocols and the reason for exclusions













































Table 2 Excluded protocols and the reason for exclusions
(Continued)
Protocol number Reason for exclusion
NCT04325672 Single-arm study
NCT04373460 Outpatient care
NCT04390503 Does not investigate population in question
NCT04375098 Does not investigate population in question
NCT04374526 Does not investigate population in question
NCT04323800 Does not investigate population in question
NCT04325672 Withdrawn
NCT04361253 Does not investigate the outcome in question
NCT04333251 Does not investigate the outcome in question
NCT04374370 Does not investigate the outcome in question
NCT04365439 Does not investigate the outcome in question
NCT04372979 Does not investigate the outcome in question
NCT04355767 Does not investigate the outcome in question
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outcome. Any disagreements will be solved by discussion
and the involvement of a third reviewer if necessary.
The quality of evidence will be assessed by the Grad-
ing of Recommendations Assessment, Development, and
Evaluation (GRADE) system. The certainty of evidence
will be classified into four levels: high, moderate, low, or
very low. Evidence is downgraded by concerns about the
risk of bias, imprecision, inconsistency, indirectness, or
publication bias. Two independent reviewers will decide
the overall quality of the evidence. A third review author
will resolve disagreements.
Patient and public involvement
No patients were or will be involved in the design, con-
duction, or interpretation of our review.
Discussion
Convalescent plasma therapy might be a good alternative
to prevent the negative effects of COVID-19, but the
clear benefits remain unclear. A prospective meta-
analysis from randomized controlled trials can fill this
void in terms of mortality, need and duration of inten-
sive care unit stay, and organ failure. Furthermore, this
protocol might serve as a basis for the not widely used
methodology of prospective meta-analysis. Although
prospective meta-analyses might include individual pa-
tient data, we do not intend to do so, corresponding au-
thors will be only contacted in the case of missing data.
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Publication policy
Based on the continuous nature of our work, we plan to publish our results
after the statistical analysis is possible for at least one subpopulation and
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our findings in peer-reviewed journals.
Trials status
Not yet started, the first systematic search is scheduled to 21 July.
Protocol amendments
Protocol amendments will be documented in the published article of results.
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